Circulating RANKL/OPG in polymyalgia rheumatica

Lia Pulsatelli, Paolo Dolzani, Tania Silvestri, Luigi Boiardi, Carlo Salvarani, Pierluigi Macchioni, Andrea Facchini, Riccardo Meliconi

Research output: Contribution to journalArticlepeer-review


Objective. To evaluate whether RAN-KL/OPG balance is modified in PMR patients, either in the active phase of the disease or during corticosteroid treatment. Methods. Circulating levels of RANKL and OPG were assayed by enzyme-linked immunosorbent assay in PMR patients with active untreated disease and in patients treated by corticosteroids over a 12-month follow-up period. Results. We found no statistically significant differences in circulating levels of OPG between PMR patients either in the active phase of the disease or during all follow-up period compared to normal controls. On the other hand, systemic production of sRANKL is increased and is not modulated by corticosteroid treatment. Conclusions. In PMR increased levels of sRANKL may be related to bone osteoporosis. Further investigations are necessary to evaluate the relationship between the RANK/RANKL/OPG system and bone turnover in PMR patients.

Original languageEnglish
Pages (from-to)621-623
Number of pages3
JournalClinical and Experimental Rheumatology
Issue number4
Publication statusPublished - Jul 2007


  • Osteoprotegerin
  • Polymyalgia rheumatica

ASJC Scopus subject areas

  • Rheumatology
  • Immunology


Dive into the research topics of 'Circulating RANKL/OPG in polymyalgia rheumatica'. Together they form a unique fingerprint.

Cite this